AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • March 1st, 2010 • Zymogenetics Inc • Biological products, (no disgnostic substances) • Washington
This AGREEMENT, dated as of July 3, 2008 (the “Effective Date”), is between ZymoGenetics, Inc., a Washington corporation (as supplemented by Section 13, the “Company”), and Darren R. Hamby (“Executive”).
THIRD RESTATED LICENSE AGREEMENT FOR IL-21 EMBODIMENTS by and between ZymoGenetics, Inc., and Novo Nordisk A/S Effective Date: December 3, 2009License Agreement • March 1st, 2010 • Zymogenetics Inc • Biological products, (no disgnostic substances) • New York
This Third Restated License Agreement for IL-21 Embodiments (as defined herein) (“Agreement”) is entered into as of December 3, 2009 (“Effective Date”) by and between ZymoGenetics, Inc., a Washington corporation (“ZGEN”), and Novo Nordisk A/S, a Danish corporation (“NN”).
Amendment To License and Collaboration AgreementLicense and Collaboration Agreement • March 1st, 2010 • Zymogenetics Inc • Biological products, (no disgnostic substances)
This Amendment (the “Amendment”) to License and Collaboration Agreement (the “Agreement”) by and between ZymoGenetics, Inc. (“ZGEN”) and Bayer Schering Pharma AG (“Bayer”) effective as of June 18, 2007 is made as of the 1st day of January 2010 (the “Effective Date”) by and among ZGEN, Bayer and ZymoGenetics, LLC, ZGEN’s assignee under the Agreement (“Zymo”). Capitalized terms not otherwise defined herein shall have those meanings set forth in the Agreement. The term, “Party” shall mean Bayer, ZGEN or Zymo and the term, “Parties” means all of them.
AMENDMENT NO. 1 TO FACILITY AGREEMENTFacility Agreement • March 1st, 2010 • Zymogenetics Inc • Biological products, (no disgnostic substances)
This AMENDMENT NO. 1 TO FACILITY AGREEMENT (this “Amendment No. 1”), dated as of October 22, 2008, is made by and among ZymoGenetics, Inc. and Deerfield Private Design Fund, L.P. and Deerfield Private Design International, L.P. (together the “Original Deerfield Lenders”) and Deerfield ZG Corporation (“DZG”).
Amendment to U.S. Co-Promotion Agreementu.s. Co-Promotion Agreement • March 1st, 2010 • Zymogenetics Inc • Biological products, (no disgnostic substances)
This amendment (the “Amendment”) to the U.S. Co-Promotion Agreement (the “Agreement”) by and between ZymoGenetics, Inc. (“ZGEN”) and Bayer HealthCare LLC (“Bayer”) effective as of June 18, 2007 is made the 1st day of January 2010 (the “Effective Date”) by and among ZGEN, Bayer and ZymoGenetics, LLC, ZGEN’s assignee under the Agreement (“Zymo”). Capitalized terms not otherwise defined herein shall have those meanings set forth in the Agreement. The term, “Party” shall mean Bayer, ZGEN or Zymo and the term, “Parties” means all of them.
AMENDMENT NO. 2 TO FACILITY AGREEMENTFacility Agreement • March 1st, 2010 • Zymogenetics Inc • Biological products, (no disgnostic substances) • New York
This AMENDMENT NO. 2 TO FACILITY AGREEMENT (this “Amendment”), dated as of December 31, 2009, is entered into by and between ZymoGenetics, Inc., a Washington corporation (the “Borrower”), and Deerfield Private Design Fund, L.P., a Delaware limited partnership, and Deerfield Private Design International, L.P., a limited partnership organized under the laws of the British Virgin Islands (individually, a “Lender” and together, the “Lenders”, and together with the Borrower, the “Parties”).
